Silence Therapeutics Plc Share Price (NASDAQ: SLN)

$4.83

▲

-0.27

(-5.29%)

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Silence Therapeutics Plc Stock chart to analyse performance

Silence Therapeutics Plc stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$4.83
Today's High:$5.14
$4.83
0.0%
Downside
Day's Volatility :6.03%
Upside
6.03%
52 Weeks Low:$1.97
52 Weeks High:$20.48
$4.83
59.21%
Downside
52 Weeks Volatility :90.38%
Upside
76.42%

Silence Therapeutics Plc Stock Returns

Period	Silence Therapeutics Plc	Sector (Health Care)	Index (Russel 2000)
3 Months	-14.83%	3.6%	0.0%
6 Months	12.96%	-7.7%	0.0%
1 Year	-74.54%	-12.6%	0.0%
3 Years	-52.2%	9.5%	-4.7%

Silence Therapeutics Plc Key Stats

Check Silence Therapeutics Plc key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$5.1
Open	$5.14
Today's High	$5.14
Today's Low	$4.83
Market Capitalization	$240.9M
Today's Volume	$31.4K
52 Week High	$20.48
52 Week Low	$1.97
Revenue TTM	$27.2M
EBITDA	$-71.3M
Earnings Per Share (EPS)	$-1.68
Profit Margin	-291.24%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-66.96%

Stock Returns calculator for Silence Therapeutics Plc Stock including INR - Dollar returns

The Silence Therapeutics Plc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Silence Therapeutics Plc investment value today

Current value as on today

₹30,480

Returns

₹69,520

(-69.52%)

Returns from Silence Therapeutics Plc Stock

₹74,804 (-74.8%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Silence Therapeutics Plc Stock

600%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Silence Therapeutics Plc Stock from India on INDmoney has increased by 600% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Silence Therapeutics Plc

Name
Holdings %
Name
Holdings %
TCG Crossover Management, LLC
6.42%
Siren, L.L.C.
6.16%
Redmile Group, LLC
4.58%
Morgan Stanley - Brokerage Accounts
4.23%
Lombard Odier Asset Management USA Corp
3.92%
Vivo Capital, LLC
2.34%

Analyst Recommendation on Silence Therapeutics Plc Stock

Rating

Trend

Buy

100%Buy

0%Hold

0%Sell

Based on 3 Wall street analysts offering stock ratings for Silence Therapeutics Plc(by analysts ranked 0 to 5 stars)

Silence Therapeutics Plc Share Price Target

What analysts predicted

Upside of 602.66%

Target:

$33.94

Current:

$4.83

Silence Therapeutics Plc share price target is $33.94, a slight Upside of 602.66% compared to current price of $4.83 as per analysts' prediction.

Silence Therapeutics Plc Stock Insights

Price Movement
In the last 7 days, SLN stock has moved down by -8.8%
Increasing Revenue
Revenue is up for the last 2 quarters, 142.0K → 224.0K (in $), with an average increase of 36.6% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -28.53M → -27.35M (in $), with an average increase of 4.3% per quarter
SLN vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 69.9% return, outperforming this stock by 144.3%
SLN vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 112.6% return, outperforming this stock by 165.2%
Price to Sales
ForSLN every $1 of sales, investors are willing to pay $8.5, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.5 for every $1 of sales.

Silence Therapeutics Plc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$319.5K	-
Net Income	$-25.6M	↑ 6.36%
Net Profit Margin	-8.0K%	-

	FY20	Y/Y Change
Revenue	$7.4M	↑ 2145.49%
Net Income	$-43.7M	↑ 66.21%
Net Profit Margin	-594.03%	↑ 7431.38%

	FY21	Y/Y Change
Revenue	$16.5M	↑ 126.59%
Net Income	$-52.4M	↑ 21.09%
Net Profit Margin	-317.44%	↑ 276.59%

	FY22	Y/Y Change
Revenue	$21.3M	↑ 40.97%
Net Income	$-49.3M	↑ 2.74%
Net Profit Margin	-231.35%	↑ 86.09%

	FY23	Y/Y Change
Revenue	$32.1M	↑ 44.99%
Net Income	$-54.8M	↑ 6.86%
Net Profit Margin	-170.51%	↑ 60.84%

	FY24	Y/Y Change
Revenue	$43.3M	↑ 70.47%
Net Income	$-45.3M	↑ 4.72%
Net Profit Margin	-104.74%	↑ 65.77%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$15.8M	↑ 491.04%
Net Income	$-2.4M	↓ 86.98%
Net Profit Margin	-15.12%	↑ 671.49%

	Q2 FY24	Q/Q Change
Revenue	$760.0K	↓ 95.18%
Net Income	$-19.8M	↑ 729.53%
Net Profit Margin	-2.6K%	↓ 2587.22%

	Q3 FY24	Q/Q Change
Revenue	$1.5M	↑ 90.97%
Net Income	$-35.7M	↑ 73.58%
Net Profit Margin	-2.4K%	↑ 237.02%

	Q4 FY24	Q/Q Change
Revenue	$24.3M	↑ 2030.28%
Net Income	$14.2M	↓ 152.47%
Net Profit Margin	58.26%	↑ 2423.58%

	Q1 FY25	Q/Q Change
Revenue	$142.0K	↓ 99.42%
Net Income	$-28.5M	↓ 301.28%
Net Profit Margin	-20.1K%	↓ 20149.81%

	Q2 FY25	Q/Q Change
Revenue	$224.0K	↑ 57.75%
Net Income	$-27.4M	↓ 4.12%
Net Profit Margin	-12.2K%	↑ 7879.94%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$319.5K	↓ 102.5%

	FY20	Y/Y Change
Profit	$2.3M	↑ 603.69%

	FY21	Y/Y Change
Profit	$6.6M	↑ 188.82%

	FY22	Y/Y Change
Profit	$8.1M	↑ 33.51%

	FY23	Y/Y Change
Profit	$19.1M	↑ 127.41%

	FY24	Y/Y Change
Profit	$31.4M	↑ 108.86%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$13.0M	↑ 1253.65%

	Q2 FY24	Q/Q Change
Profit	$-2.6M	↓ 120.01%

	Q3 FY24	Q/Q Change
Profit	$-2.2M	↓ 20.0%

	Q4 FY24	Q/Q Change
Profit	$22.7M	↓ 1492.25%

	Q1 FY25	Q/Q Change
Profit	$88.0K	↓ 99.61%

	Q2 FY25	Q/Q Change
Profit	$139.0K	↑ 57.95%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$2.3M	↓ 110.3%
Investing Cash Flow	$-19.7M	↑ 210.87%
Financing Cash Flow	$6.9M	↑ 1446.33%

	FY20	Y/Y Change
Operating Cash Flow	$-14.5M	↓ 723.97%
Investing Cash Flow	$12.9M	↓ 164.06%
Financing Cash Flow	$20.7M	↑ 192.58%

	FY21	Y/Y Change
Operating Cash Flow	$9.1M	↓ 163.16%
Investing Cash Flow	$11.5M	↓ 9.79%
Financing Cash Flow	$40.9M	↑ 99.06%

	FY22	Y/Y Change
Operating Cash Flow	$-55.3M	↓ 767.88%
Investing Cash Flow	$-20.1M	↓ 290.66%
Financing Cash Flow	$52.4M	↑ 40.17%

	FY23	Y/Y Change
Operating Cash Flow	$-49.8M	↓ 13.43%
Investing Cash Flow	$20.8M	↓ 199.32%
Financing Cash Flow	$31.8M	↓ 41.57%

	FY24	Y/Y Change
Operating Cash Flow	$-67.6M	↑ 71.89%
Investing Cash Flow	$-22.0M	↓ 233.69%
Financing Cash Flow	$142.1M	↑ 464.85%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-9.5M	↓ 36.84%
Investing Cash Flow	$-49.6M	↓ 10317.8%
Financing Cash Flow	$134.2M	↑ 964.15%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-6.1M	↓ 35.77%
Investing Cash Flow	$696.5K	↓ 101.4%
Financing Cash Flow	$1.1M	↓ 99.2%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-26.0M	↑ 308.31%
Investing Cash Flow	$-38.1M	↓ 5362.96%
Financing Cash Flow	$7.9M	↑ 604.6%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-24.9M	↑ 26.5%
Investing Cash Flow	$68.1M	↓ 336.22%
Financing Cash Flow	$19.9M	↑ 233.08%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-12.3M	↓ 50.5%
Investing Cash Flow	$-44.4M	↓ 165.14%
Financing Cash Flow	$14.0K	↓ 99.93%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-21.8M	↑ 76.98%
Investing Cash Flow	$-1.6M	↓ 96.48%
Financing Cash Flow	$1000.0	↓ 92.86%

Silence Therapeutics Plc Technicals Summary

Sell

Neutral

Buy

Silence Therapeutics Plc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Silence Therapeutics Plc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Silence Therapeutics Plc	-20.91%	12.96%	-74.54%	-52.2%	-79.72%
Regeneron Pharmaceuticals, Inc.	6.48%	-15.2%	-50.31%	-3.3%	-2.01%
Beone Medicines Ltd	1.77%	24.81%	62.78%	79.11%	29.69%
Vertex Pharmaceuticals Incorporated	-14.45%	-19.13%	-17.84%	34.68%	41.87%
Alnylam Pharmaceuticals, Inc.	13.79%	83.28%	75.87%	111.28%	242.25%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Silence Therapeutics Plc	NA	NA	NA	-1.21	-0.67	-0.22	NA	1.99
Regeneron Pharmaceuticals, Inc.	14.6	14.6	1.2	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.73	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.86	27.86	0.58	18.06	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Silence Therapeutics Plc	Buy	$240.9M	-79.72%	NA	-291.24%
Regeneron Pharmaceuticals, Inc.	Buy	$61.4B	-2.01%	14.6	31.37%
Beone Medicines Ltd	NA	$36.5B	29.69%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$100.5B	41.87%	27.86	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$59.5B	242.25%	NA	-12.96%

About Silence Therapeutics Plc

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated lipoprotein(a); Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trial for the treatment of genetic hematological conditions, including polycythemia vera; and SLN548 for complement-mediated disease. Silence Therapeutics plc has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Hansoh Pharmaceutical Group Company Limited to develop siRNAs. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

Organization	Silence Therapeutics Plc
Employees	116
CEO	Mr. Craig A. Tooman M.B.A.
Industry	Health Technology

Key Management of Silence Therapeutics Plc

Name	Title
Mr. Craig A. Tooman M.B.A.	President, CEO & Executive Director
Ms. Rhonda L. Hellums	Executive VP, CFO & Secretary
Dr. Steven J. Romano M.D.	Executive VP and Chief Research & Development Officer
Dr. Marie Wikstrom Lindholm Ph.D.	Chief Scientific Officer
Ms. Gem Gokmen Hopkins	Head of IR & Corporate Communications
Ms. Gianine Esposito	Chief Human Resources Officer
Dr. Barbara A. Ruskin J.D., Ph.D.	Senior VP and Chief Intellectual Property & Innovation Officer
Mr. J.P. Gabriel	Chief Technical Operations Officer
Mr. Curtis Rambaran M.D.	Chief Medical Officer

Important FAQs about investing in SLN Stock from India :

What is Silence Therapeutics Plc share price today?

Silence Therapeutics Plc share price today is $4.83 as on August 30, 2025 at 1:29 am IST at the close of the market. Silence Therapeutics Plc share today touched a day high of $5.14 and a low of $4.83.

What is the 52 week high and 52 week low for Silence Therapeutics Plc share?

Silence Therapeutics Plc share touched a 52 week high of $20.48 and a 52 week low of $1.97. Silence Therapeutics Plc stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $4.83, lower by 76.42% versus the 52 week high.

How to invest in Silence Therapeutics Plc Stock (SLN) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Silence Therapeutics Plc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Silence Therapeutics Plc Shares that will get you 0.3106 shares as per Silence Therapeutics Plc share price of $4.83 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Silence Therapeutics Plc Stock (SLN) from India?

Indian investors can start investing in Silence Therapeutics Plc (SLN) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Silence Therapeutics Plc stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Silence Therapeutics Plc share’s latest price of $4.83 as on August 30, 2025 at 1:29 am IST, you will get 2.0704 shares of Silence Therapeutics Plc. Learn more about fractional shares .

What are the returns that Silence Therapeutics Plc has given to Indian investors in the last 5 years?

Silence Therapeutics Plc stock has given -79.72% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?